Rehman Mujeeb Ur, Ali Sobia Sabir, Khan Nawaz, Ahmad Ibrar, Ullah Irfan
Diabetes and Endocrinology Division, MTI Lady Reading Hospital, Peshawar, Pakistan.
J Ayub Med Coll Abbottabad. 2020 Jul-Sep;32(3):395-399.
Thyroid disorders are the second most common of the endocrine diseases. With regards to Hypothyroidism, it has a slow indolent course over the years, before its diagnosis. Most of the patient, on adequate treatment with biochemical euthyroid status, have generalised symptoms that affect their quality of life. Several tools to assess quality of life in thyroid disorders have been validated and recommended for use for those patients in clinical follow ups. ThyPRO 39 is one of a recently developed thyroid-specific quality of life (QoL) questionnaires applicable to patients with benign thyroid disorders (BTD). The purpose of this study was to predict the thyroid-related quality of life (QoL) instrument ThyPRO 39 in patients with Hypothyroidism, who were rendered euthyroid with thyroid replacement therapy prior to the administration of study tool and to assess the internal reliability of this scale in our population.
A sample of 52 patients undergoing maintenance treatment for Hypothyroidism who visited the outpatient Endocrinology clinics at Lady Reading Hospital was studied. They were interviewed for their baseline demographic details and details on ThyPRO 39 questionnaire were recorded after a written informed consent. The data was entered and analysed using SPSS 25. The Internal reliability of the ThyPRO 39 scale was assessed for multi-item scales using Cronbach's alpha coefficient.
The ThyPRO 39 scale demonstrated good response across the whole range of QoL aspects in patients with hypothyroidism. Internal reliability for ThyPRO 39 scale was satisfactory. Cronbach's Alpha in our study was 0.928, which was comparable to the results of other studies.
We suggest implementing this measurement tool as a patient-reported outcome in clinical studies in our indigenous population and further more to utilise it as a screening tool for QoL in clinical management of Hypothyroidism in our routine medical consultations.
甲状腺疾病是第二常见的内分泌疾病。关于甲状腺功能减退症,在其被诊断之前,多年来病情发展缓慢且隐匿。大多数接受充分治疗并达到生化甲状腺功能正常状态的患者,仍有影响其生活质量的全身性症状。已经有几种评估甲状腺疾病患者生活质量的工具得到验证,并被推荐用于临床随访中的这些患者。ThyPRO 39是最近开发的一种适用于良性甲状腺疾病(BTD)患者的甲状腺特异性生活质量(QoL)问卷。本研究的目的是预测甲状腺功能减退症患者使用甲状腺替代疗法使甲状腺功能恢复正常后,在使用研究工具之前的甲状腺相关生活质量(QoL)工具ThyPRO 39,并评估该量表在我们人群中的内部信度。
对52名在拉迪德夫人医院门诊内分泌科接受甲状腺功能减退症维持治疗的患者进行了研究。在获得书面知情同意后,询问了他们的基线人口统计学细节,并记录了关于ThyPRO 39问卷的详细信息。使用SPSS 25输入和分析数据。使用克朗巴赫α系数评估ThyPRO 39量表多项目量表的内部信度。
ThyPRO 39量表在甲状腺功能减退症患者的整个生活质量方面都显示出良好的反应。ThyPRO 39量表的内部信度令人满意。我们研究中的克朗巴赫α系数为0.928,与其他研究结果相当。
我们建议在我们的本土人群的临床研究中采用这种测量工具作为患者报告的结局,并且进一步在我们的常规医疗咨询中,将其用作甲状腺功能减退症临床管理中生活质量的筛查工具。